Regulation of fibroblast growth factor 23 (FGF23) in health and disease

FEBS Letters

article

Ludmilla Bär¹  Christos Stournaras²  Florian Lang³  Michael Föller⁴ 

[1] Institute of Agricultural and Nutritional Sciences, Martin Luther University Halle-Wittenberg;Institute of Biochemistry, University of Crete Medical School;Institute of Physiology, University of Tübingen;Institute of Physiology, University of Hohenheim

关键词: FGF23;    phosphate;    inflammation;    Ca2+;    Klotho;   

DOI  :  10.1002/1873-3468.13494

来源: John Wiley & Sons Ltd.

【 摘 要 】

Fibroblast growth factor 23 (FGF23) is mainly produced in the bone and, upon secretion, forms a complex with a FGF receptor and coreceptor aKlotho. FGF23 can exert several endocrine functions, such as inhibiting renal phosphate reabsorption and 1,25-dihydroxyvitamin D3 production. Moreover, it has paracrine activities on several cell types, including neutrophils and hepatocytes. Klotho and Fgf23 deficiencies result in pathologies otherwise encountered in age-associated diseases, mainly as a result of hyperphosphataemia-dependent calcification. FGF23 levels are also perturbed in the plasma of patients with several disorders, including kidney or cardiovascular diseases. Here, we review mechanisms controlling FGF23 production and discuss how FGF23 regulation is perturbed in disease.

【 授权许可】

Unknown